Profile data is unavailable for this security.
About the company
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
- Revenue in USD (TTM)27.10m
- Net income in USD-24.31m
- Incorporated2007
- Employees101.00
- LocationCapricor Therapeutics Inc8840 Wilshire Blvd, 2nd FloorBEVERLY HILLS 90211United StatesUSA
- Phone+1 (310) 358-3200
- Fax+1 (302) 655-5049
- Websitehttps://capricor.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Rezolute Inc | 0.00 | -58.21m | 158.53m | 51.00 | -- | 2.24 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 158.61m | 51.00 | -- | 0.6053 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
Lifecore Biomedical Inc | 103.27m | -64.24m | 158.84m | 459.00 | -- | -- | -- | 1.54 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
Syros Pharmaceuticals Inc | 6.98m | -144.49m | 160.37m | 68.00 | -- | 10.65 | -- | 22.97 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
Alpha Tau Medical Ltd | 0.00 | -28.95m | 160.53m | 121.00 | -- | 2.03 | -- | -- | -0.4165 | -0.4165 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -26.50 | -- | -28.08 | -- | -- | -- | -- | -- | -- | -- | 0.0653 | -- | -- | -- | 13.64 | -- | -- | -- |
Repare Therapeutics Inc | 97.86m | -45.69m | 161.29m | 179.00 | -- | 0.6894 | -- | 1.65 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
Caribou Biosciences Inc | 33.40m | -115.26m | 161.67m | 158.00 | -- | 0.4709 | -- | 4.84 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Vigil Neuroscience Inc | 0.00 | -82.78m | 162.74m | 65.00 | -- | 1.57 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
Galectin Therapeutics Inc | 0.00 | -44.78m | 162.83m | 14.00 | -- | -- | -- | -- | -0.7373 | -0.7373 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -177.94 | -92.08 | -373.85 | -121.97 | -- | -- | -- | -- | -- | -10.24 | 7.25 | -- | -- | -- | -15.26 | -- | -- | -- |
Telomir Pharmaceuticals Inc | 0.00 | -18.84m | 162.85m | 1.00 | -- | 53.99 | -- | -- | -0.6889 | -0.6889 | 0.00 | 0.1019 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.8986 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
Capricor Therapeutics Inc | 27.10m | -24.31m | 164.47m | 101.00 | -- | 8.86 | -- | 6.07 | -0.8755 | -0.8755 | 0.9574 | 0.5834 | 0.5246 | -- | 59.13 | 268,299.50 | -47.07 | -54.12 | -122.20 | -75.13 | -- | -- | -89.72 | -316.25 | -- | -- | 0.1548 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Alimera Sciences Inc | 90.22m | -22.66m | 166.07m | 159.00 | -- | 4.08 | -- | 1.84 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
Rigel Pharmaceuticals Inc | 120.35m | -19.80m | 167.16m | 147.00 | -- | -- | -- | 1.39 | -0.1135 | -0.1135 | 0.69 | -0.1806 | 0.9623 | 0.9241 | 4.23 | 818,680.30 | -15.83 | -28.82 | -30.14 | -47.26 | 93.22 | 97.88 | -16.45 | -35.76 | 1.17 | -2.91 | 2.13 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
OptiNose Inc | 74.02m | -30.75m | 167.29m | 132.00 | -- | -- | -- | 2.26 | -0.2733 | -0.2733 | 0.659 | -0.8777 | 0.7453 | 0.8764 | 4.74 | 560,772.80 | -30.91 | -48.25 | -- | -98.95 | 88.98 | 86.96 | -41.47 | -131.66 | 2.17 | -1.16 | 4.16 | -- | -6.93 | 58.64 | 52.58 | -- | -27.96 | -- |
INmune Bio Inc | 131.00k | -34.50m | 167.95m | 11.00 | -- | 5.25 | -- | 1,282.08 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
Achieve Life Sciences Inc | 0.00 | -27.32m | 168.27m | 22.00 | -- | 3.39 | -- | -- | -1.29 | -1.29 | 0.00 | 1.44 | 0.00 | -- | -- | 0.00 | -60.15 | -86.31 | -109.37 | -119.59 | -- | -- | -- | -- | -- | -9.33 | 0.2574 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.36m | 4.31% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 378.14k | 1.20% |
Geode Capital Management LLCas of 31 Mar 2024 | 328.48k | 1.04% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 305.04k | 0.97% |
Millennium Management LLCas of 31 Mar 2024 | 293.04k | 0.93% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 197.93k | 0.63% |
American Portfolios Advisors, Inc.as of 31 Mar 2024 | 149.20k | 0.47% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 120.31k | 0.38% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 116.72k | 0.37% |
Arrowstreet Capital LPas of 31 Mar 2024 | 101.54k | 0.32% |